Supreme Court Attacks Dept. of Labor Actions In Sales Rep Overtime Case
This article was originally published in The Pink Sheet Daily
Executive Summary
The high court questioned the nature of pharmaceutical sales rep work and what constitutes a sale in the case Christopher v. SmithKline Beecham; Justice Stephen Breyer asked GSK’s attorney what the court should say in crafting an opinion.
You may also be interested in...
Supreme Court’s Pro-Pharma Decision On Sales Rep Overtime Reproves Informal Agency Policymaking
Court rules that reps’ nonbinding commitments from physicians to prescribe drugs constitute a sale and thus make them outside sales employees who are exempt from overtime. Court also rebukes Labor Department’s policy change outside of rulemaking.
Sales Reps Overtime Suit Goes To Supreme Court; Could The IMS Win Bite Pharma?
The high court will hear oral arguments on whether sales reps sell drugs or just promote them; Thomas Goldstein, who won a victory for PhRMA in Sorrell v. IMS, is representing the sales reps and former Solicitor General Paul Clement is arguing for GlaxoSmithKline.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.